

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2877)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 27 MAY 2022

The Board is pleased to announce that all the Resolutions as set out in the notice of AGM were duly passed at the AGM held on 27 May 2022.

Reference is made to the circular (the “**Circular**”) of China Shineway Pharmaceutical Group Limited (the “**Company**”) dated 28 April 2022. Capitalised terms used in this announcement shall have the same meanings as those used in the Circular unless otherwise stated.

The Board announces that at the AGM all proposed resolutions (the “**Resolutions**”) as set out in the notice of the AGM dated 28 April 2022 were put to the AGM for voting by poll. At the AGM, all the Resolutions as set out in the notice of the AGM were duly passed and the poll results are as follows:

DESCRIPTIONS OF THE ORDINARY RESOLUTIONS ^{Note}		Number of votes (%)	
		FOR	AGAINST
1.	To receive and consider the audited consolidated financial statements, the report of the Directors and the report of the independent auditor for the year ended 31 December 2021.	639,167,753 (99.677%)	2,070,488 (0.323%)
2.	(A) To re-elect Mr. LI Zhenjiang as Director.	610,933,914 (95.274%)	30,304,327 (4.726%)
	(B) To re-elect Ms. XIN Yunxia as Director.	605,398,564 (94.411%)	35,839,677 (5.589%)
	(C) To re-elect Ms. CHENG Li as Director.	608,816,808 (94.944%)	32,421,433 (5.056%)
	(D) To re-elect Mr. LIU Shun Fai as Director.	640,174,629 (99.834%)	1,063,612 (0.166%)
	(E) To authorize the Board to fix the remuneration of the Directors.	641,217,241 (99.997%)	21,000 (0.003%)
3.	To re-appoint Deloitte Touche Tohmatsu as auditor and to authorize the Board to fix their remuneration.	638,030,891 (99.500%)	3,207,350 (0.500%)

DESCRIPTIONS OF THE ORDINARY RESOLUTIONS ^{Note}		Number of votes (%)	
		FOR	AGAINST
4.	To grant a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company.	638,704,996 (99.605%)	2,533,245 (0.395%)
5.	To grant a general mandate to the Directors to allot, issue and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company.	566,223,633 (88.302%)	75,014,608 (11.698%)
6.	To extend the general mandate to allot, issue and deal with additional shares of the Company by adding thereto an amount representing the number of shares repurchased by the Company.	567,438,372 (88.491%)	73,799,869 (11.509%)

Note: The full text of the resolutions was set out in the notice of the AGM which formed part of the Circular.

As more than 50% of the votes were cast in favour of each of the Resolutions, all the Resolutions were duly passed as ordinary resolutions at the AGM.

As at the date of the AGM, the total number of issued shares of the Company was 827,000,000 shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against any of the Resolutions at the AGM. There were no Shares entitling any Shareholders to attend and abstain from voting in favour of any of the Resolutions at the AGM as set out in Rule 13.40 of the Listing Rules, and there were no Shares requiring the Shareholders to abstain from voting at the AGM under the Listing Rules. No person has indicated in the Circular that he/she/it intends to abstain from voting or vote against any of the Resolutions at the AGM.

Computershare Hong Kong Investor Services Limited, the Hong Kong branch share registrar of the Company, acted as scrutineer for the vote-taking at the AGM.

By order of the Board
China Shineway Pharmaceutical Group Limited
Li Zhenjiang
Chairman

Hong Kong, 27 May 2022

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Chen Zhong; the non-executive Director is Mr. Zhou Wencheng and the independent non-executive Directors are Ms. Cheng Li, Prof. Luo Guoan and Mr. Liu Shun Fai.